Anantin (linear sequence)

CAS No. 133658-45-4

Anantin (linear sequence)( ——— )

Catalog No. M42218 CAS No. 133658-45-4

Anantin binds competitively to the receptor of atrial natriuretic factor (ANF) from bovine adrenal cortex (Kd = 0.6 μM) and acts as natriuretic peptide receptor A antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Anantin (linear sequence)
  • Note
    Research use only, not for human use.
  • Brief Description
    Anantin binds competitively to the receptor of atrial natriuretic factor (ANF) from bovine adrenal cortex (Kd = 0.6 μM) and acts as natriuretic peptide receptor A antagonist.
  • Description
    Anantin binds competitively to the receptor of atrial natriuretic factor (ANF) from bovine adrenal cortex (Kd = 0.6 μM) and acts as natriuretic peptide receptor A antagonist.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    133658-45-4
  • Formula Weight
    1871
  • Molecular Formula
    C90H111N21O24
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wyss DF,et al. Anantin--a peptide antagonist of the atrial natriuretic factor (ANF). II. Determination of the primary sequence by NMR on the basis of proton assignments. J Antibiot (Tokyo). 1991
molnova catalog
related products
  • 4-O-Feruloylquinic a...

    4-O-Feruloylquinic acid can be useful for the prevention of cardiovascular and other chronic diseases.

  • Codrituzumab

    Codrituzumab (GC3) is a humanized antibody against the glypican-3 hepatocellular carcinoma protein that can be used in combination with sorafenib to study incurable advanced hepatocellular carcinoma (HCC).

  • Isoviolanthin

    Isoviolanthin reduces the migratory and invasive capacities of TGF-β1-treated HCC cells but exhibits no cytotoxic effects on normal live cells, and has potential as a therapeutic agent for the treatment of advanced-stage metastatic HCC.